Study of BL-M07D1 combination for advanced HER2-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new combination therapy (BL-M07D1 plus another drug) for people with advanced HER2-positive stomach or gastroesophageal junction cancer. It aims to see if the combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- Your cancer is HER2-positive and advanced (spread or cannot be removed by surgery) and is a type called adenocarcinoma
- You have at least one tumor that can be measured on scans
- You are in good general health (able to do daily activities without help, and your organs are working well)
- You have not had certain types of chemotherapy or an ADC drug with a camptothecin derivative in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Hear when a new HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.